{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T11:24:31Z","timestamp":1787397871345,"version":"build-2736575974"},"reference-count":107,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-026-04348-y","type":"journal-article","created":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T15:28:28Z","timestamp":1775748508000},"page":"4160-4180","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeted and molecular therapies in Ewing sarcoma: a comprehensive review of preclinical and clinical advances"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-8831-2986","authenticated-orcid":false,"given":"Christ\u00e8le","family":"Asmar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Asmar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Awad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Boutros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reina","family":"Khatib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaza","family":"Hammad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caren","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Mallory","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Masrouha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,9]]},"reference":[{"key":"4348_CR1","unstructured":"Durer S, Gasalberti DP, Shaikh H. Ewing Sarcoma. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 [cited 2026 Mar 16]. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK559183\/. Accessed 16 Mar 2026"},{"key":"4348_CR2","doi-asserted-by":"publisher","first-page":"3526","DOI":"10.1002\/cncr.24388","volume":"115","author":"MU Jawad","year":"2009","unstructured":"Jawad MU, Cheung MC, Min ES, Schneiderbauer MM, Koniaris LG, Scully SP. Ewing sarcoma demonstrates racial disparities in incidence-related and sex-related differences in outcome: an analysis of 1631 cases from the SEER database, 1973-2005. Cancer. 2009;115:3526\u201336. https:\/\/doi.org\/10.1002\/cncr.24388.","journal-title":"Cancer"},{"key":"4348_CR3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0005415","volume":"4","author":"M Kauer","year":"2009","unstructured":"Kauer M, Ban J, Kofler R, Walker B, Davis S, Meltzer P, et al. A molecular function map of Ewing\u2019s sarcoma. PLoS ONE. 2009;4:e5415. https:\/\/doi.org\/10.1371\/journal.pone.0005415.","journal-title":"PLoS ONE"},{"key":"4348_CR4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.17_suppl.LBA2","volume":"40","author":"M McCabe","year":"2022","unstructured":"McCabe M, Kirton L, Khan M, Fenwick N, Strauss SJ, Valverde C, et al. Phase III assessment of topotecan and cyclophosphamide and high-dose ifosfamide in rEECur: an international randomized controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma (RR-ES). J Clin Oncol. 2022;40:LBA2-LBA2. https:\/\/doi.org\/10.1200\/JCO.2022.40.17_suppl.LBA2.","journal-title":"J Clin Oncol"},{"key":"4348_CR5","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s40272-013-0037-1","volume":"15","author":"C Owens","year":"2013","unstructured":"Owens C, Abbott LS, Gupta AA. Optimal management of Ewing sarcoma family of tumors: recent developments in systemic therapy. Paediatr Drugs. 2013;15:473\u201392. https:\/\/doi.org\/10.1007\/s40272-013-0037-1.","journal-title":"Paediatr Drugs"},{"key":"4348_CR6","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.2147\/OTT.S170585","volume":"12","author":"D Van Mater","year":"2019","unstructured":"Van Mater D, Wagner L. Management of recurrent Ewing sarcoma: challenges and approaches. Onco Targets Ther. 2019;12:2279\u201388. https:\/\/doi.org\/10.2147\/OTT.S170585.","journal-title":"Onco Targets Ther"},{"key":"4348_CR7","doi-asserted-by":"publisher","first-page":"369","DOI":"10.4103\/0019-5413.69305","volume":"44","author":"S Jain","year":"2010","unstructured":"Jain S, Kapoor G. Chemotherapy in Ewing\u2019s sarcoma. Indian J Orthop. 2010;44:369\u201377. https:\/\/doi.org\/10.4103\/0019-5413.69305.","journal-title":"Indian J Orthop"},{"key":"4348_CR8","doi-asserted-by":"publisher","first-page":"7393","DOI":"10.1128\/mcb.13.12.7393-7398.1993","volume":"13","author":"WA May","year":"1993","unstructured":"May WA, Lessnick SL, Braun BS, Klemsz M, Lewis BC, Lunsford LB, et al. The Ewing\u2019s sarcoma EWS\/FLI-1 fusion gene encodes a more potent transcriptional activator and is a more powerful transforming gene than FLI-1. Mol Cell Biol. 1993;13:7393\u20138. https:\/\/doi.org\/10.1128\/mcb.13.12.7393-7398.1993.","journal-title":"Mol Cell Biol"},{"key":"4348_CR9","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aam8429","volume":"10","author":"SK Z\u00f6llner","year":"2017","unstructured":"Z\u00f6llner SK, Selvanathan SP, Graham GT, Commins RMT, Hong SH, Moseley E, et al. Inhibition of the oncogenic fusion protein EWS-FLI1 causes G2 -M cell cycle arrest and enhanced vincristine sensitivity in Ewing\u2019s sarcoma. Science Signaling. 2017;10:eaam8429. https:\/\/doi.org\/10.1126\/scisignal.aam8429.","journal-title":"Science Signaling"},{"key":"4348_CR10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.11500","volume":"39","author":"JA Ludwig","year":"2021","unstructured":"Ludwig JA, Federman NC, Anderson PM, Macy ME, Riedel RF, Davis LE, et al. TK216 for relapsed\/refractory Ewing sarcoma: interim phase 1\/2 results. J Clin Oncol. 2021;39:11500\u201311500. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.11500.","journal-title":"J Clin Oncol"},{"key":"4348_CR11","doi-asserted-by":"publisher","first-page":"3725","DOI":"10.1200\/JCO.24.00020","volume":"42","author":"PA Meyers","year":"2024","unstructured":"Meyers PA, Federman N, Daw N, Anderson PM, Davis LE, Kim A, et al. Open-label, multicenter, phase I\/II, first-in-human trial of TK216: A first-generation EWS::FLI1 fusion protein antagonist in Ewing Sarcoma. J Clin Oncol. 2024;42:3725\u201334. https:\/\/doi.org\/10.1200\/JCO.24.00020.","journal-title":"J Clin Oncol"},{"key":"4348_CR12","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1158\/1078-0432.CCR-13-0901","volume":"20","author":"PJ Grohar","year":"2014","unstructured":"Grohar PJ, Segars LE, Yeung C, Pommier Y, D\u2019Incalci M, Mendoza A, et al. Dual targeting of EWS-FLI1 activity and the associated DNA damage response with trabectedin and SN38 synergistically inhibits Ewing Sarcoma cell growth. Clin Cancer Res. 2014;20:1190\u2013203. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-0901.","journal-title":"Clin Cancer Res"},{"key":"4348_CR13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.11519","volume":"41","author":"P Grohar","year":"2023","unstructured":"Grohar P, Ballman KV, Heise R, Glod J, Wedekind MF, Mascarenhas L, et al. SARC037: Results of phase I study of trabectedin given as a 1-hour (h) infusion in combination with low dose irinotecan in relapsed\/refractory Ewing sarcoma (ES). J Clin Oncol. 2023;41:11519\u201311519. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.11519.","journal-title":"J Clin Oncol"},{"key":"4348_CR14","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.ejca.2011.09.027","volume":"48","author":"S Baruchel","year":"2012","unstructured":"Baruchel S, Pappo A, Krailo M, Baker KS, Wu B, Villaluna D, et al. A phase 2 trial of trabectedin in children with recurrent rhabdomyosarcoma, Ewing sarcoma and non-rhabdomyosarcoma soft tissue sarcomas: a report from the Children\u2019s Oncology Group. Eur J Cancer. 2012;48:579\u201385. https:\/\/doi.org\/10.1016\/j.ejca.2011.09.027.","journal-title":"Eur J Cancer"},{"key":"4348_CR15","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.ccell.2017.12.009","volume":"33","author":"AB Iniguez","year":"2018","unstructured":"Iniguez AB, Stolte B, Wang EJ, Conway AS, Alexe G, Dharia NV, et al. EWS\/FLI confers tumor cell synthetic lethality to CDK12 inhibition in ewing sarcoma. Cancer Cell. 2018;33:202-216.e6. https:\/\/doi.org\/10.1016\/j.ccell.2017.12.009.","journal-title":"Cancer Cell"},{"key":"4348_CR16","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1158\/1535-7163.MCT-20-0489","volume":"20","author":"DAR Heisey","year":"2021","unstructured":"Heisey DAR, Jacob S, Lochmann TL, Kurupi R, Ghotra MS, Calbert ML, et al. Pharmaceutical interference of the EWS-FLI1\u2013driven transcriptome by cotargeting H3K27ac and RNA polymerase activity in Ewing sarcoma. Mol Cancer Ther. 2021;20:1868\u201379. https:\/\/doi.org\/10.1158\/1535-7163.MCT-20-0489.","journal-title":"Mol Cancer Ther"},{"key":"4348_CR17","doi-asserted-by":"publisher","first-page":"4584","DOI":"10.1158\/1078-0432.CCR-14-0072","volume":"20","author":"S Sankar","year":"2014","unstructured":"Sankar S, Theisen ER, Bearss J, Mulvihill T, Hoffman LM, Sorna V, et al. Reversible LSD1 inhibition interferes with global EWS\/ETS transcriptional activity and impedes ewing sarcoma tumor growth. Clin Cancer Res. 2014;20:4584\u201397. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-0072.","journal-title":"Clin Cancer Res"},{"key":"4348_CR18","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/s41417-025-00887-8","volume":"32","author":"ST Cervera","year":"2025","unstructured":"Cervera ST, Mart\u00ednez S, Iranzo-Mart\u00ednez M, Notario L, Melero-Fern\u00e1ndez De Mera RM, Alonso J. Targeted inactivation of EWSR1\u202f:\u202f: FLI1 gene in Ewing sarcoma via CRISPR\/Cas9 driven by an Ewing-specific GGAA promoter. Cancer Gene Ther. 2025;32:437\u201349. https:\/\/doi.org\/10.1038\/s41417-025-00887-8.","journal-title":"Cancer Gene Ther"},{"key":"4348_CR19","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1186\/s12943-024-02115-7","volume":"23","author":"E Wei","year":"2024","unstructured":"Wei E, Mitanoska A, O\u2019Brien Q, Porter K, Molina M, Ahsan H, et al. Pharmacological targeting of P300\/CBP reveals EWS::FLI1-mediated senescence evasion in Ewing sarcoma. Mol Cancer. 2024;23:222. https:\/\/doi.org\/10.1186\/s12943-024-02115-7.","journal-title":"Mol Cancer"},{"key":"4348_CR20","doi-asserted-by":"publisher","first-page":"13396","DOI":"10.1021\/jacs.4c18484","volume":"147","author":"Z Zhu","year":"2025","unstructured":"Zhu Z, Chen H, Qiu X, Kaniskan HU, Xie L, Chen X, et al. (GGAA)3 -Based TF-PROTACs enable targeted degradation of ETV6 to inhibit Ewing Sarcoma growth. J Am Chem Soc. 2025;147:13396\u2013404. https:\/\/doi.org\/10.1021\/jacs.4c18484.","journal-title":"J Am Chem Soc"},{"key":"4348_CR21","doi-asserted-by":"crossref","first-page":"B244","DOI":"10.1158\/1535-7163.MCT-06-0408","volume":"6","author":"M Rosenfeld-Franklin","year":"2007","unstructured":"Rosenfeld-Franklin M, Cooke A, Pirritt C, Landfair D, Silva S, Turton R, et al. In vivo evaluation of OSI-906, a novel small molecule kinase inhibitor of the insulin-like growth factor-1 receptor (IGF-1R). Mol Cancer Ther. 2007;6:B244\u2013B244.","journal-title":"Mol Cancer Ther"},{"key":"4348_CR22","doi-asserted-by":"publisher","first-page":"3016","DOI":"10.1200\/jco.2010.28.15_suppl.3016","volume":"28","author":"VM Macaulay","year":"2010","unstructured":"Macaulay VM, Middleton MR, Eckhardt SG, Juergens RA, Stephens AW, Poondru S, et al. Phase I study of OSI-906, dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR) in combination with erlotinib (E) in patients with advanced solid tumors. JCO. 2010;28:3016\u20133016. https:\/\/doi.org\/10.1200\/jco.2010.28.15_suppl.3016.","journal-title":"JCO"},{"key":"4348_CR23","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1002\/pbc.22741","volume":"56","author":"EA Kolb","year":"2011","unstructured":"Kolb EA, Gorlick R, Lock R, Carol H, Morton CL, Keir ST, et al. Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program. Pediatr Blood Cancer. 2011;56:595\u2013603. https:\/\/doi.org\/10.1002\/pbc.22741.","journal-title":"Pediatr Blood Cancer"},{"key":"4348_CR24","doi-asserted-by":"publisher","first-page":"4874","DOI":"10.18632\/aging.204117","volume":"14","author":"X Wang","year":"2022","unstructured":"Wang X, Zhou P, Lin L, Wu B, Fu Z, Huang X, et al. Effective natural inhibitors targeting IGF-1R by computational study. Aging. 2022;14:4874\u201387. https:\/\/doi.org\/10.18632\/aging.204117.","journal-title":"Aging"},{"key":"4348_CR25","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ejca.2005.09.015","volume":"42","author":"K Scotlandi","year":"2006","unstructured":"Scotlandi K, Perdichizzi S, Bernard G, Nicoletti G, Nanni P, Lollini P-L, et al. Targeting CD99 in association with doxorubicin: An effective combined treatment for Ewing\u2019s sarcoma. Eur J Cancer. 2006;42:91\u20136. https:\/\/doi.org\/10.1016\/j.ejca.2005.09.015.","journal-title":"Eur J Cancer"},{"key":"4348_CR26","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1002\/jmr.2276","volume":"26","author":"AL Ramon","year":"2013","unstructured":"Ramon AL, Bertrand JR, De Martimprey H, Bernard G, Ponchel G, Malvy C, et al. siRNA associated with immunonanoparticles directed against CD99 antigen improves gene expression inhibition in vivo in Ewing\u2019s sarcoma. J Mol Recognit. 2013;26:318\u201329. https:\/\/doi.org\/10.1002\/jmr.2276.","journal-title":"J Mol Recognit"},{"key":"4348_CR27","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1158\/0008-5472.CAN-11-3648","volume":"72","author":"JC Brenner","year":"2012","unstructured":"Brenner JC, Feng FY, Han S, Patel S, Goyal SV, Bou-Maroun LM, et al. PARP-1 inhibition as a targeted strategy to treat Ewing\u2019s sarcoma. Cancer Res. 2012;72:1608\u201313. https:\/\/doi.org\/10.1158\/0008-5472.CAN-11-3648.","journal-title":"Cancer Res"},{"key":"4348_CR28","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.celrep.2014.09.028","volume":"9","author":"E Stewart","year":"2014","unstructured":"Stewart E, Goshorn R, Bradley C, Griffiths LM, Benavente C, Twarog NR, et al. Targeting the DNA repair pathway in Ewing sarcoma. Cell Rep. 2014;9:829\u201340. https:\/\/doi.org\/10.1016\/j.celrep.2014.09.028.","journal-title":"Cell Rep"},{"key":"4348_CR29","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1002\/cncr.33349","volume":"127","author":"R Chugh","year":"2021","unstructured":"Chugh R, Ballman KV, Helman LJ, Patel S, Whelan JS, Widemann B, et al. SARC025 arms 1 and 2: A phase 1 study of the poly(ADP\u2010ribose) polymerase inhibitor niraparib with temozolomide or irinotecan in patients with advanced Ewing sarcoma. Cancer. 2021;127:1301\u201310. https:\/\/doi.org\/10.1002\/cncr.33349.","journal-title":"Cancer"},{"key":"4348_CR30","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1158\/1078-0432.CCR-14-2572","volume":"21","author":"MA Smith","year":"2015","unstructured":"Smith MA, Reynolds CP, Kang MH, Kolb EA, Gorlick R, Carol H, et al. Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the Pediatric Preclinical Testing Program. Clin Cancer Res. 2015;21:819\u201332. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-2572.","journal-title":"Clin Cancer Res"},{"key":"4348_CR31","doi-asserted-by":"publisher","DOI":"10.1177\/17588359231213841","volume":"15","author":"A Adibi","year":"2023","unstructured":"Adibi A, Tokat \u00dcM, \u00d6zg\u00fc E, Ayd\u0131n E, Demiray \u0130, Demiray M. PARP inhibitor combinations with high-dose vitamin C in the treatment of Ewing sarcoma: two case reports and mechanistic overview. Ther Adv Med Oncol. 2023;15:17588359231213841. https:\/\/doi.org\/10.1177\/17588359231213841.","journal-title":"Ther Adv Med Oncol"},{"key":"4348_CR32","doi-asserted-by":"publisher","first-page":"3541","DOI":"10.1158\/1078-0432.CCR-22-3897","volume":"29","author":"L Ramos","year":"2023","unstructured":"Ramos L, Truong S, Zhai B, Joshi J, Ghaidi F, Lizardo MM, et al. A bifunctional PARP-HDAC inhibitor with activity in Ewing sarcoma. Clin Cancer Res. 2023;29:3541\u201353. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-3897.","journal-title":"Clin Cancer Res"},{"key":"4348_CR33","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.molcel.2012.04.009","volume":"46","author":"A Aguilera","year":"2012","unstructured":"Aguilera A, Garc\u00eda-Muse T. R loops: from transcription byproducts to threats to genome stability. Mol Cell. 2012;46:115\u201324. https:\/\/doi.org\/10.1016\/j.molcel.2012.04.009.","journal-title":"Mol Cell"},{"key":"4348_CR34","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/nature25748","volume":"555","author":"A Gorthi","year":"2018","unstructured":"Gorthi A, Romero JC, Loranc E, Cao L, Lawrence LA, Goodale E, et al. EWS\u2013FLI1 increases transcription to cause R-loops and block BRCA1 repair in Ewing sarcoma. Nature. 2018;555:387\u201391. https:\/\/doi.org\/10.1038\/nature25748.","journal-title":"Nature"},{"key":"4348_CR35","doi-asserted-by":"publisher","first-page":"11005","DOI":"10.1200\/JCO.2017.35.15_suppl.11005","volume":"35","author":"S Attia","year":"2017","unstructured":"Attia S, Bolejack V, Ganjoo KN, George S, Agulnik M, Rushing DA, et al. A phase II trial of regorafenib (REGO) in patients (pts) with advanced Ewing sarcoma and related tumors (EWS) of soft tissue and bone: SARC024 trial results. J Clin Oncol. 2017;35:11005\u201311005. https:\/\/doi.org\/10.1200\/JCO.2017.35.15_suppl.11005.","journal-title":"J Clin Oncol"},{"key":"4348_CR36","doi-asserted-by":"publisher","first-page":"18872","DOI":"10.1002\/cam4.6515","volume":"12","author":"H Peretz Soroka","year":"2023","unstructured":"Peretz Soroka H, Vora T, Noujaim J, Marcoux N, Cohen\u2010Gogo S, Alcindor T, et al. Real\u2010world experience of tyrosine kinase inhibitors in children, adolescents and adults with relapsed or refractory bone tumours: a Canadian Sarcoma Research and Clinical Collaboration ( CanSaRCC ) study. Cancer Med. 2023;12:18872\u201381. https:\/\/doi.org\/10.1002\/cam4.6515.","journal-title":"Cancer Med"},{"key":"4348_CR37","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/S1470-2045(19)30825-3","volume":"21","author":"A Italiano","year":"2020","unstructured":"Italiano A, Mir O, Mathoulin-Pelissier S, Penel N, Piperno-Neumann S, Bompas E, et al. Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2020;21:446\u201355. https:\/\/doi.org\/10.1016\/S1470-2045(19)30825-3.","journal-title":"Lancet Oncol"},{"key":"4348_CR38","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.27077","volume":"65","author":"MK Chuk","year":"2018","unstructured":"Chuk MK, Widemann BC, Minard CG, Liu X, Kim A, Bernhardt MB, et al. A phase 1 study of cabozantinib in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: Trial ADVL1211, a report from the Children\u2019s Oncology Group. Pediatr Blood Cancer. 2018;65:e27077. https:\/\/doi.org\/10.1002\/pbc.27077.","journal-title":"Pediatr Blood Cancer"},{"key":"4348_CR39","doi-asserted-by":"publisher","first-page":"10010","DOI":"10.1200\/JCO.2021.39.15_suppl.10010","volume":"39","author":"S Akshintala","year":"2021","unstructured":"Akshintala S, Widemann BC, Barkauskas DA, Hall D, Reid JM, Voss SD, et al. Phase 2 trial of cabozantinib in children and young adults with refractory sarcomas, Wilms tumor, and rare tumors: Children\u2019s Oncology Group Study (ADVL1622). J Clin Oncol. 2021;39:10010\u201310010. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.10010.","journal-title":"J Clin Oncol"},{"key":"4348_CR40","doi-asserted-by":"publisher","first-page":"e1256","DOI":"10.1002\/onco.13726","volume":"26","author":"J Xu","year":"2021","unstructured":"Xu J, Xie L, Sun X, Liu K, Tang X, Yan T, et al. Anlotinib, vincristine, and irinotecan for advanced Ewing sarcoma after failure of standard multimodal therapy: a two-cohort, phase Ib\/II trial. Oncologist. 2021;26:e1256\u201362. https:\/\/doi.org\/10.1002\/onco.13726.","journal-title":"Oncologist"},{"key":"4348_CR41","doi-asserted-by":"publisher","DOI":"10.1007\/s00894-020-04470-w","volume":"26","author":"V Guaitoli","year":"2020","unstructured":"Guaitoli V, Alvarez-Ginarte YM, Montero-Cabrera LA, Bencomo-Mart\u00ednez A, Badel YP, Giorgetti A, et al. A computational strategy to understand structure-activity relationship of 1,3-disubstituted imidazole [1,5-\u03b1] pyrazine derivatives described as ATP competitive inhibitors of the IGF-1 receptor related to Ewing sarcoma. J Mol Model. 2020;26:222. https:\/\/doi.org\/10.1007\/s00894-020-04470-w.","journal-title":"J Mol Model"},{"key":"4348_CR42","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12020304","volume":"12","author":"HSG Richter","year":"2020","unstructured":"Richter HSG, Hensel T, Schmidt O, Saratov V, Von Heyking K, Becker-Dettling F, et al. Combined inhibition of epigenetic readers and transcription initiation targets the EWS-ETS transcriptional program in Ewing sarcoma. Cancers. 2020;12:304. https:\/\/doi.org\/10.3390\/cancers12020304.","journal-title":"Cancers"},{"key":"4348_CR43","doi-asserted-by":"publisher","unstructured":"Hensel T, Giorgi C, Schmidt O, Calzada-Wack J, Neff F, Buch T, et al. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma. Oncotarget. 2016;7:1451\u201363. https:\/\/doi.org\/10.18632\/oncotarget.6385","DOI":"10.18632\/oncotarget.6385"},{"key":"4348_CR44","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1158\/1535-7163.MCT-18-1151","volume":"18","author":"SN Loganathan","year":"2019","unstructured":"Loganathan SN, Tang N, Holler AE, Wang N, Wang J. Targeting the IGF1R\/PI3K\/AKT pathway sensitizes Ewing sarcoma to BET bromodomain inhibitors. Mol Cancer Ther. 2019;18:929\u201336. https:\/\/doi.org\/10.1158\/1535-7163.MCT-18-1151.","journal-title":"Mol Cancer Ther"},{"key":"4348_CR45","doi-asserted-by":"publisher","first-page":"4525","DOI":"10.1158\/0008-5472.CAN-16-1040","volume":"76","author":"N Shukla","year":"2016","unstructured":"Shukla N, Somwar R, Smith RS, Ambati S, Munoz S, Merchant M, et al. Proteasome addiction defined in Ewing sarcoma is effectively targeted by a novel class of 19S proteasome inhibitors. Cancer Res. 2016;76:4525\u201334. https:\/\/doi.org\/10.1158\/0008-5472.CAN-16-1040.","journal-title":"Cancer Res"},{"key":"4348_CR46","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1002\/pbc.24874","volume":"61","author":"R Bagatell","year":"2014","unstructured":"Bagatell R, Norris R, Ingle A, Ahern C, Voss S, Fox E, et al. Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: a Children\u2019s Oncology Group study. Pediatr Blood Cancer. 2014;61:833\u20139. https:\/\/doi.org\/10.1002\/pbc.24874.","journal-title":"Pediatr Blood Cancer"},{"key":"4348_CR47","unstructured":"St. Jude Children's Research Hospital. Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors [Internet]; 2025. https:\/\/clinicaltrials.gov\/study\/NCT01946529. Accessed 30 Sept 2025"},{"key":"4348_CR48","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ejca.2016.03.084","volume":"62","author":"D Frappaz","year":"2016","unstructured":"Frappaz D, Federico SM, Pearson ADJ, Gore L, Macy ME, DuBois SG, et al. Phase 1 study of dalotuzumab monotherapy and ridaforolimus\u2013dalotuzumab combination therapy in paediatric patients with advanced solid tumours. Eur J Cancer. 2016;62:9\u201317. https:\/\/doi.org\/10.1016\/j.ejca.2016.03.084.","journal-title":"Eur J Cancer"},{"key":"4348_CR49","doi-asserted-by":"publisher","first-page":"10463","DOI":"10.2147\/CMAR.S208720","volume":"11","author":"P Munster","year":"2019","unstructured":"Munster P, Mita M, Mahipal A, Nemunaitis J, Massard C, Mikkelsen T, et al. First-in-human phase I study of a dual mTOR kinase and DNA-PK inhibitor (CC-115) in advanced malignancy. CMAR. 2019;11:10463\u201376. https:\/\/doi.org\/10.2147\/CMAR.S208720.","journal-title":"CMAR"},{"key":"4348_CR50","doi-asserted-by":"publisher","first-page":"28895","DOI":"10.18632\/oncotarget.5000","volume":"6","author":"C Giorgi","year":"2015","unstructured":"Giorgi C, Boro A, Rechfeld F, Lopez-Garcia LA, Gierisch ME, Sch\u00e4fer BW, et al. PI3K\/AKT signaling modulates transcriptional expression of EWS\/FLI1 through specificity protein 1. Oncotarget. 2015;6:28895\u2013910. https:\/\/doi.org\/10.18632\/oncotarget.5000.","journal-title":"Oncotarget"},{"key":"4348_CR51","doi-asserted-by":"publisher","first-page":"30178","DOI":"10.18632\/oncotarget.4903","volume":"6","author":"AL Kennedy","year":"2015","unstructured":"Kennedy AL, Vallurupalli M, Chen L, Crompton B, Cowley G, Vazquez F, et al. Functional, chemical genomic, and super-enhancer screening identify sensitivity to cyclin D1\/CDK4 pathway inhibition in Ewing sarcoma. Oncotarget. 2015;6:30178\u201393. https:\/\/doi.org\/10.18632\/oncotarget.4903.","journal-title":"Oncotarget"},{"key":"4348_CR52","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1158\/1078-0432.CCR-18-0372","volume":"25","author":"LM Guenther","year":"2019","unstructured":"Guenther LM, Dharia NV, Ross L, Conway A, Robichaud AL, Catlett JL, et al. A combination CDK4\/6 and IGF1R inhibitor strategy for Ewing Sarcoma. Clin Cancer Res. 2019;25:1343\u201357. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-0372.","journal-title":"Clin Cancer Res"},{"key":"4348_CR53","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15204911","volume":"15","author":"SM Turaga","year":"2023","unstructured":"Turaga SM, Vishwakarma V, Hembruff SL, Gibbs BK, Sabu P, Puri RV, et al. Inducing mitotic catastrophe as a therapeutic approach to improve outcomes in Ewing Sarcoma. Cancers. 2023;15:4911. https:\/\/doi.org\/10.3390\/cancers15204911.","journal-title":"Cancers"},{"key":"4348_CR54","doi-asserted-by":"publisher","first-page":"58759","DOI":"10.18632\/oncotarget.11643","volume":"7","author":"M Nieto-Soler","year":"2016","unstructured":"Nieto-Soler M, Morgado-Palacin I, Lafarga V, Lecona E, Murga M, Callen E, et al. Efficacy of ATR inhibitors as single agents in Ewing sarcoma. Oncotarget. 2016;7:58759\u201367. https:\/\/doi.org\/10.18632\/oncotarget.11643.","journal-title":"Oncotarget"},{"key":"4348_CR55","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aam9078","volume":"9","author":"AG Henssen","year":"2017","unstructured":"Henssen AG, Reed C, Jiang E, Garcia HD, Von Stebut J, MacArthur IC, et al. Therapeutic targeting of PGBD5-induced DNA repair dependency in pediatric solid tumors. Sci Transl Med. 2017;9:eaam9078. https:\/\/doi.org\/10.1126\/scitranslmed.aam9078.","journal-title":"Sci Transl Med"},{"key":"4348_CR56","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1158\/1541-7786.MCR-06-0090","volume":"4","author":"M Kinsey","year":"2006","unstructured":"Kinsey M, Smith R, Lessnick SL. NR0B1 is required for the oncogenic phenotype mediated by EWS\/FLI in Ewing\u2019s sarcoma. Mol Cancer Res. 2006;4:851\u20139. https:\/\/doi.org\/10.1158\/1541-7786.MCR-06-0090.","journal-title":"Mol Cancer Res"},{"key":"4348_CR57","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24119332","volume":"24","author":"M Yasir","year":"2023","unstructured":"Yasir M, Park J, Han E-T, Park WS, Han J-H, Kwon Y-S, et al. Investigation of flavonoid scaffolds as DAX1 inhibitors against Ewing Sarcoma through pharmacoinformatic and dynamic simulation studies. Int J Mol Sci. 2023;24:9332. https:\/\/doi.org\/10.3390\/ijms24119332.","journal-title":"Int J Mol Sci"},{"key":"4348_CR58","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/S1470-2045(20)30023-1","volume":"21","author":"KL Davis","year":"2020","unstructured":"Davis KL, Fox E, Merchant MS, Reid JM, Kudgus RA, Liu X, et al. Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1\u20132 trial. Lancet Oncol. 2020;21:541\u201350. https:\/\/doi.org\/10.1016\/S1470-2045(20)30023-1.","journal-title":"Lancet Oncol"},{"key":"4348_CR59","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1016\/S1470-2045(17)30624-1","volume":"18","author":"HA Tawbi","year":"2017","unstructured":"Tawbi HA, Burgess M, Bolejack V, Van Tine BA, Schuetze SM, Hu J, et al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol. 2017;18:1493\u2013501. https:\/\/doi.org\/10.1016\/S1470-2045(17)30624-1.","journal-title":"Lancet Oncol"},{"key":"4348_CR60","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1200\/JCO.22.01815","volume":"41","author":"SG DuBois","year":"2023","unstructured":"DuBois SG, Krailo MD, Glade-Bender J, Buxton A, Laack N, Randall RL, et al. Randomized phase III trial of Ganitumab with interval-compressed chemotherapy for patients with newly diagnosed metastatic Ewing Sarcoma: a report from the Children\u2019s Oncology Group. JCO. 2023;41:2098\u2013107. https:\/\/doi.org\/10.1200\/JCO.22.01815.","journal-title":"JCO"},{"key":"4348_CR61","doi-asserted-by":"publisher","first-page":"3219","DOI":"10.1016\/j.ejca.2013.06.010","volume":"49","author":"P Sch\u00f6ffski","year":"2013","unstructured":"Sch\u00f6ffski P, Adkins D, Blay J-Y, Gil T, Elias AD, Rutkowski P, et al. An open-label, phase 2 study evaluating the efficacy and safety of the anti-IGF-1R antibody cixutumumab in patients with previously treated advanced or metastatic soft-tissue sarcoma or Ewing family of tumours. Eur J Cancer. 2013;49:3219\u201328. https:\/\/doi.org\/10.1016\/j.ejca.2013.06.010.","journal-title":"Eur J Cancer"},{"key":"4348_CR62","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1002\/pbc.25334","volume":"62","author":"LM Wagner","year":"2015","unstructured":"Wagner LM, Fouladi M, Ahmed A, Krailo MD, Weigel B, DuBois SG, et al. Phase II study of cixutumumab in combination with temsirolimus in pediatric patients and young adults with recurrent or refractory sarcoma: a report from the Children\u2019s Oncology Group. Pediatr Blood Cancer. 2015;62:440\u20134. https:\/\/doi.org\/10.1002\/pbc.25334.","journal-title":"Pediatr Blood Cancer"},{"key":"4348_CR63","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/S1470-2045(13)70049-4","volume":"14","author":"GK Schwartz","year":"2013","unstructured":"Schwartz GK, Tap WD, Qin L-X, Livingston MB, Undevia SD, Chmielowski B, et al. Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial. Lancet Oncol. 2013;14:371\u201382. https:\/\/doi.org\/10.1016\/S1470-2045(13)70049-4.","journal-title":"Lancet Oncol"},{"key":"4348_CR64","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1158\/1078-0432.CCR-12-0061","volume":"18","author":"A Naing","year":"2012","unstructured":"Naing A, LoRusso P, Fu S, Hong DS, Anderson P, Benjamin RS, et al. Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing\u2019s sarcoma family tumors. Clin Cancer Res. 2012;18:2625\u201331. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-0061.","journal-title":"Clin Cancer Res"},{"key":"4348_CR65","doi-asserted-by":"publisher","first-page":"4534","DOI":"10.1200\/JCO.2010.33.0670","volume":"29","author":"H Juergens","year":"2011","unstructured":"Juergens H, Daw NC, Geoerger B, Ferrari S, Villarroel M, Aerts I, et al. Preliminary efficacy of the anti-insulin-like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma. J Clin Oncol. 2011;29:4534\u201340. https:\/\/doi.org\/10.1200\/JCO.2010.33.0670.","journal-title":"J Clin Oncol"},{"key":"4348_CR66","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1038\/mt.2015.43","volume":"23","author":"M Ghisoli","year":"2015","unstructured":"Ghisoli M, Barve M, Schneider R, Mennel R, Lenarsky C, Wallraven G, et al. Pilot trial of FANG immunotherapy in Ewing\u2019s sarcoma. Mol Ther. 2015;23:1103\u20139. https:\/\/doi.org\/10.1038\/mt.2015.43.","journal-title":"Mol Ther"},{"key":"4348_CR67","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1002\/mpo.1303","volume":"38","author":"R Dagher","year":"2002","unstructured":"Dagher R, Long LM, Read EJ, Leitman SF, Carter CS, Tsokos M, et al. Pilot trial of tumor-specific peptide vaccination and continuous infusion interleukin-2 in patients with recurrent Ewing sarcoma and alveolar rhabdomyosarcoma: an inter-institute NIH study\u2020. Med Pediatr Oncol. 2002;38:158\u201364. https:\/\/doi.org\/10.1002\/mpo.1303.","journal-title":"Med Pediatr Oncol"},{"key":"4348_CR68","doi-asserted-by":"publisher","first-page":"4850","DOI":"10.1158\/1078-0432.CCR-07-4065","volume":"14","author":"CL Mackall","year":"2008","unstructured":"Mackall CL, Rhee EH, Read EJ, Khuu HM, Leitman SF, Bernstein D, et al. A pilot study of consolidative immunotherapy in patients with high-risk pediatric sarcomas. Clin Cancer Res. 2008;14:4850\u20138. https:\/\/doi.org\/10.1158\/1078-0432.CCR-07-4065.","journal-title":"Clin Cancer Res"},{"key":"4348_CR69","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1038\/mt.2016.86","volume":"24","author":"M Ghisoli","year":"2016","unstructured":"Ghisoli M, Barve M, Mennel R, Lenarsky C, Horvath S, Wallraven G, et al. Three-year follow up of GMCSF\/bi-shRNAfurin DNA-transfected autologous tumor immunotherapy (Vigil) in metastatic advanced Ewing\u2019s sarcoma. Mol Ther. 2016;24:1478\u201383. https:\/\/doi.org\/10.1038\/mt.2016.86.","journal-title":"Mol Ther"},{"key":"4348_CR70","unstructured":"Gradalis, Inc. A multi-center phase III, Randomized, open-label trial of vigil (Bi-shRNAfurin and GMCSF augmented autologous tumor cell immunotherapy) in combination with irinotecan and temozolomide as a second-line regimen for Ewing's Sarcoma [Internet]. https:\/\/clinicaltrials.gov\/study\/NCT03495921. Accessed 30 Sept 2025"},{"key":"4348_CR71","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1186\/s13046-021-02125-z","volume":"40","author":"O Schmidt","year":"2021","unstructured":"Schmidt O, Nehls N, Prexler C, Von Heyking K, Groll T, Pardon K, et al. Class I histone deacetylases (HDAC) critically contribute to Ewing sarcoma pathogenesis. J Exp Clin Cancer Res. 2021;40:322. https:\/\/doi.org\/10.1186\/s13046-021-02125-z.","journal-title":"J Exp Clin Cancer Res"},{"key":"4348_CR72","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1158\/2767-9764.CRC-25-0058","volume":"5","author":"SL Koppenhafer","year":"2025","unstructured":"Koppenhafer SL, Geary EL, Thomas MV, Croushore EE, Zimmerman JAO, Gedminas JM, et al. Histone deacetylase inhibitors target DNA replication regulators and replication stress in Ewing sarcoma cells. Cancer Res Commun. 2025;5:1034\u201348. https:\/\/doi.org\/10.1158\/2767-9764.CRC-25-0058.","journal-title":"Cancer Res Commun"},{"key":"4348_CR73","unstructured":"National Center for Tumor Diseases, Heidelberg. Phase I\/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma or leukemia [Internet]; 2018. https:\/\/clinicaltrials.gov\/study\/NCT01422499. Accessed 30 Sept 2025"},{"key":"4348_CR74","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0142704","volume":"10","author":"VB Sampson","year":"2015","unstructured":"Sampson VB, Vetter NS, Kamara DF, Collier AB, Gresh RC, Kolb EA. Vorinostat enhances cytotoxicity of SN-38 and temozolomide in Ewing sarcoma cells and activates STAT3\/AKT\/MAPK pathways. PLoS ONE. 2015;10:e0142704. https:\/\/doi.org\/10.1371\/journal.pone.0142704.","journal-title":"PLoS ONE"},{"key":"4348_CR75","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1200\/JCO.2007.11.9230","volume":"26","author":"JLG Bender","year":"2008","unstructured":"Bender JLG, Adamson PC, Reid JM, Xu L, Baruchel S, Shaked Y, et al. Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a children\u2019s oncology group study. JCO. 2008;26:399\u2013405. https:\/\/doi.org\/10.1200\/JCO.2007.11.9230.","journal-title":"JCO"},{"key":"4348_CR76","doi-asserted-by":"publisher","first-page":"96","DOI":"10.18632\/genesandcancer.218","volume":"12","author":"P Jayabal","year":"2021","unstructured":"Jayabal P, Ma X, Shiio Y. EZH2 suppresses endogenous retroviruses and an interferon response in cancers. Genes Cancer. 2021;12:96\u2013105. https:\/\/doi.org\/10.18632\/genesandcancer.218.","journal-title":"Genes Cancer"},{"key":"4348_CR77","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ejca.2020.04.031","volume":"135","author":"L Amoroso","year":"2020","unstructured":"Amoroso L, Castel V, Bisogno G, Casanova M, Marquez-Vega C, Chisholm JC, et al. Phase II results from a phase I\/II study to assess the safety and efficacy of weekly nab-paclitaxel in paediatric patients with recurrent or refractory solid tumours: a collaboration with the European Innovative Therapies for Children with Cancer Network. Eur J Cancer. 2020;135:89\u201397. https:\/\/doi.org\/10.1016\/j.ejca.2020.04.031.","journal-title":"Eur J Cancer"},{"key":"4348_CR78","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-025-13691-2","volume":"25","author":"J Ziener","year":"2025","unstructured":"Ziener J, Henao-Restrepo JA, Leonhardi J, Sturm M-J, Becker S, Morales-Prieto DM, et al. Combined inhibition of ribonucleotide reductase and WEE1 induces synergistic anticancer activity in Ewing\u2019s sarcoma cells. BMC Cancer. 2025;25:277. https:\/\/doi.org\/10.1186\/s12885-025-13691-2.","journal-title":"BMC Cancer"},{"key":"4348_CR79","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1158\/1078-0432.CCR-19-3470","volume":"26","author":"KA Cole","year":"2020","unstructured":"Cole KA, Pal S, Kudgus RA, Ijaz H, Liu X, Minard CG, et al. Phase I clinical trial of the Wee1 inhibitor adavosertib (AZD1775) with irinotecan in children with relapsed solid tumors: a COG phase I consortium report (ADVL1312). Clin Cancer Res. 2020;26:1213\u20139. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-3470.","journal-title":"Clin Cancer Res"},{"key":"4348_CR80","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1158\/1535-7163.MCT-23-0641","volume":"23","author":"VJ Collins","year":"2024","unstructured":"Collins VJ, Ludwig KR, Nelson AE, Sundara Rajan S, Yeung C, Vulikh K, et al. Enhancing standard of care chemotherapy efficacy using DNA-dependent protein kinase (DNA-PK) inhibition in preclinical models of Ewing Sarcoma. Mol Cancer Ther. 2024;23:1109\u201323. https:\/\/doi.org\/10.1158\/1535-7163.MCT-23-0641.","journal-title":"Mol Cancer Ther"},{"key":"4348_CR81","doi-asserted-by":"publisher","first-page":"3229","DOI":"10.1158\/1078-0432.CCR-18-2675","volume":"25","author":"YP Moss\u00e9","year":"2019","unstructured":"Moss\u00e9 YP, Fox E, Teachey DT, Reid JM, Safgren SL, Carol H, et al. A phase II study of Alisertib in children with recurrent\/refractory solid tumors or leukemia: Children\u2019s Oncology Group Phase I and pilot consortium (ADVL0921). Clin Cancer Res. 2019;25:3229\u201338. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-2675.","journal-title":"Clin Cancer Res"},{"key":"4348_CR82","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/pbc.22430","volume":"55","author":"JM Maris","year":"2010","unstructured":"Maris JM, Morton CL, Gorlick R, Kolb EA, Lock R, Carol H, et al. Initial testing of the aurora kinase a inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP). Pediatr Blood Cancer. 2010;55:26\u201334. https:\/\/doi.org\/10.1002\/pbc.22430.","journal-title":"Pediatr Blood Cancer"},{"key":"4348_CR83","doi-asserted-by":"publisher","first-page":"6172","DOI":"10.1200\/JCO.2005.11.429","volume":"23","author":"NC Daw","year":"2005","unstructured":"Daw NC, Furman WL, Stewart CF, Iacono LC, Krailo M, Bernstein ML, et al. Phase I and pharmacokinetic study of Gefitinib in children with refractory solid tumors: a Children\u2019s Oncology Group study. J Clin Oncol. 2005;23:6172\u201380. https:\/\/doi.org\/10.1200\/JCO.2005.11.429.","journal-title":"J Clin Oncol"},{"key":"4348_CR84","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1007\/s00432-009-0554-z","volume":"135","author":"T Yamamoto","year":"2009","unstructured":"Yamamoto T, Ohno T, Wakahara K, Nagano A, Kawai G, Saitou M, et al. Simultaneous inhibition of mitogen-activated protein kinase and phosphatidylinositol 3-kinase pathways augment the sensitivity to actinomycin D in Ewing sarcoma. J Cancer Res Clin Oncol. 2009;135:1125\u201336. https:\/\/doi.org\/10.1007\/s00432-009-0554-z.","journal-title":"J Cancer Res Clin Oncol"},{"key":"4348_CR85","doi-asserted-by":"publisher","first-page":"38483","DOI":"10.1021\/acsami.9b12682","volume":"11","author":"A Zaritski","year":"2019","unstructured":"Zaritski A, Castillo-Ecija H, Kumarasamy M, Peled E, Sverdlov Arzi R, Carcaboso \u00c1M, et al. Selective accumulation of galactomannan amphiphilic nanomaterials in pediatric solid tumor xenografts correlates with GLUT1 gene expression. ACS Appl Mater Interfaces. 2019;11:38483\u201396. https:\/\/doi.org\/10.1021\/acsami.9b12682.","journal-title":"ACS Appl Mater Interfaces"},{"key":"4348_CR86","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-025-03956-4","author":"M K\u00fchne","year":"2025","unstructured":"K\u00fchne M, Becker S, Sonnemann J, Marx C. TH-302 (evofosfamide) monotherapy exerts anticancer activity in Ewing\u2019s sarcoma cells under hypoxia. Clin Transl Oncol. 2025. https:\/\/doi.org\/10.1007\/s12094-025-03956-4.","journal-title":"Clin Transl Oncol"},{"key":"4348_CR87","doi-asserted-by":"publisher","first-page":"5060","DOI":"10.1158\/0008-5472.CAN-19-0217","volume":"79","author":"C Yeung","year":"2019","unstructured":"Yeung C, Gibson AE, Issaq SH, Oshima N, Baumgart JT, Edessa LD, et al. Targeting glycolysis through inhibition of lactate dehydrogenase impairs tumor growth in preclinical models of Ewing sarcoma. Cancer Res. 2019;79:5060\u201373. https:\/\/doi.org\/10.1158\/0008-5472.CAN-19-0217.","journal-title":"Cancer Res"},{"key":"4348_CR88","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2022.106311","volume":"131","author":"\u017d Zajec","year":"2023","unstructured":"Zajec \u017d, Dernov\u0161ek J, Distel M, Gobec M, Toma\u0161i\u010d T. Optimisation of pyrazolo[1,5-a]pyrimidin-7(4H)-one derivatives as novel Hsp90 c-terminal domain inhibitors against Ewing sarcoma. Bioorg Chem. 2023;131:106311. https:\/\/doi.org\/10.1016\/j.bioorg.2022.106311.","journal-title":"Bioorg Chem"},{"key":"4348_CR89","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2024.107850","volume":"153","author":"J Dernov\u0161ek","year":"2024","unstructured":"Dernov\u0161ek J, Urban\u010di\u010d D, Zajec \u017d, Sturtzel C, Grissenberger S, Wenninger-Weinzierl A, et al. First dual inhibitors of human topoisomerase II\u03b1 and Hsp90 c-terminal domain inhibit the growth of Ewing sarcoma in vitro and in vivo. Bioorg Chem. 2024;153:107850. https:\/\/doi.org\/10.1016\/j.bioorg.2024.107850.","journal-title":"Bioorg Chem"},{"key":"4348_CR90","doi-asserted-by":"publisher","DOI":"10.1038\/s41389-020-00294-8","volume":"10","author":"L Bierbaumer","year":"2021","unstructured":"Bierbaumer L, Katschnig AM, Radic-Sarikas B, Kauer MO, Petro JA, H\u00f6gler S, et al. YAP\/TAZ inhibition reduces metastatic potential of Ewing sarcoma cells. Oncogenesis. 2021;10:2. https:\/\/doi.org\/10.1038\/s41389-020-00294-8.","journal-title":"Oncogenesis"},{"key":"4348_CR91","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.876602","volume":"13","author":"C Cristalli","year":"2022","unstructured":"Cristalli C, Manara MC, Valente S, Pellegrini E, Bavelloni A, De Feo A, et al. Novel targeting of DNA methyltransferase activity inhibits Ewing sarcoma cell proliferation and enhances tumor cell sensitivity to DNA damaging drugs by activating the DNA damage response. Front Endocrinol. 2022;13:876602. https:\/\/doi.org\/10.3389\/fendo.2022.876602.","journal-title":"Front Endocrinol"},{"key":"4348_CR92","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1002\/pbc.21274","volume":"50","author":"A Langevin","year":"2008","unstructured":"Langevin A, Bernstein M, Kuhn JG, Blaney SM, Ivy P, Sun J, et al. A phase II trial of rebeccamycin analogue (NSC #655649) in children with solid tumors: a Children\u2019s Oncology Group study. Pediatr Blood Cancer. 2008;50:577\u201380. https:\/\/doi.org\/10.1002\/pbc.21274.","journal-title":"Pediatr Blood Cancer"},{"key":"4348_CR93","doi-asserted-by":"publisher","first-page":"63003","DOI":"10.18632\/oncotarget.11416","volume":"7","author":"KL Goss","year":"2016","unstructured":"Goss KL, Gordon DJ. Gene expression signature based screening identifies ribonucleotide reductase as a candidate therapeutic target in Ewing sarcoma. Oncotarget. 2016;7:63003\u201319. https:\/\/doi.org\/10.18632\/oncotarget.11416.","journal-title":"Oncotarget"},{"key":"4348_CR94","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.pathol.2019.03.012","volume":"51","author":"B-J Noh","year":"2019","unstructured":"Noh B-J, Jung W-W, Kim H-S, Park Y-K. Pathogenetic implications of early growth response 1 in Ewing sarcoma. Pathology. 2019;51:605\u20139. https:\/\/doi.org\/10.1016\/j.pathol.2019.03.012.","journal-title":"Pathology"},{"key":"4348_CR95","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-49667-2","volume":"15","author":"L Yu","year":"2024","unstructured":"Yu L, Deng Y, Wang X, Santos C, Davis IJ, Earp HS, et al. Co-targeting JAK1\/STAT6\/GAS6\/TAM signaling improves chemotherapy efficacy in Ewing sarcoma. Nat Commun. 2024;15:5292. https:\/\/doi.org\/10.1038\/s41467-024-49667-2.","journal-title":"Nat Commun"},{"key":"4348_CR96","doi-asserted-by":"publisher","first-page":"172","DOI":"10.18632\/oncotarget.454","volume":"3","author":"JS Barber-Rotenberg","year":"2012","unstructured":"Barber-Rotenberg JS, Selvanathan SP, Kong Y, Erkizan HV, Snyder TM, Hong SP, et al. Single enantiomer of YK-4-279 demonstrates specificity in targeting the oncogene EWS-FLI1. Oncotarget. 2012;3:172\u201382. https:\/\/doi.org\/10.18632\/oncotarget.454.","journal-title":"Oncotarget"},{"key":"4348_CR97","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1634\/theoncologist.11-5-503","volume":"11","author":"M Bernstein","year":"2006","unstructured":"Bernstein M, Kovar H, Paulussen M, Randall RL, Schuck A, Teot LA, et al. Ewing\u2019s sarcoma family of tumors: current management. Oncologist. 2006;11:503\u201319. https:\/\/doi.org\/10.1634\/theoncologist.11-5-503.","journal-title":"Oncologist"},{"key":"4348_CR98","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1038\/nm.1983","volume":"15","author":"HV Erkizan","year":"2009","unstructured":"Erkizan HV, Kong Y, Merchant M, Schlottmann S, Barber-Rotenberg JS, Yuan L, et al. A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase a inhibits growth of Ewing\u2019s sarcoma. Nat Med. 2009;15:750\u20136. https:\/\/doi.org\/10.1038\/nm.1983.","journal-title":"Nat Med"},{"key":"4348_CR99","doi-asserted-by":"publisher","first-page":"3036","DOI":"10.1200\/JCO.2014.59.5256","volume":"33","author":"N Gaspar","year":"2015","unstructured":"Gaspar N, Hawkins DS, Dirksen U, Lewis IJ, Ferrari S, Le Deley M-C, et al. Ewing sarcoma: current management and future approaches through collaboration. J Clin Oncol. 2015;33:3036\u201346. https:\/\/doi.org\/10.1200\/JCO.2014.59.5256.","journal-title":"J Clin Oncol"},{"key":"4348_CR100","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1358\/dot.2007.43.10.1148059","volume":"43","author":"WW Ma","year":"2007","unstructured":"Ma WW, Jimeno A. Temsirolimus. Drugs Today. 2007;43:659\u201369. https:\/\/doi.org\/10.1358\/dot.2007.43.10.1148059.","journal-title":"Drugs Today"},{"key":"4348_CR101","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.ejca.2020.06.014","volume":"137","author":"SM Federico","year":"2020","unstructured":"Federico SM, Pappo AS, Sahr N, Sykes A, Campagne O, Stewart CF, et al. A phase I trial of talazoparib and irinotecan with and without temozolomide in children and young adults with recurrent or refractory solid malignancies. Eur J Cancer. 2020;137:204\u201313. https:\/\/doi.org\/10.1016\/j.ejca.2020.06.014.","journal-title":"Eur J Cancer"},{"key":"4348_CR102","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10081685","volume":"10","author":"SK Z\u00f6llner","year":"2021","unstructured":"Z\u00f6llner SK, Amatruda JF, Bauer S, Collaud S, de \u00c1lava E, DuBois SG, et al. Ewing sarcoma-diagnosis, treatment, clinical challenges and future perspectives. J Clin Med. 2021;10:1685. https:\/\/doi.org\/10.3390\/jcm10081685.","journal-title":"J Clin Med"},{"key":"4348_CR103","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-3028","author":"M Krumbholz","year":"2016","unstructured":"Krumbholz M, Hellberg J, Steif B, B\u00e4uerle T, Gillmann C, Fritscher T, et al. Genomic EWSR1 fusion sequence as highly sensitive and dynamic plasma tumor marker in Ewing sarcoma. Clin Cancer Res. 2016. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-3028.","journal-title":"Clin Cancer Res"},{"key":"4348_CR104","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2023-CT019","volume":"83","author":"SA Gatz","year":"2023","unstructured":"Gatz SA, Sim\u00f3n ARS, Archambaud B, Abbou S, Cleirec M, Leruste A, et al. Abstract CT019: phase I\/II study of the PARP inhibitor olaparib and ATR inhibitor ceralasertib in children with advanced malignancies: arm N of the AcS\u00e9-ESMART trial. Cancer Res. 2023;83:CT019. https:\/\/doi.org\/10.1158\/1538-7445.AM2023-CT019.","journal-title":"Cancer Res"},{"key":"4348_CR105","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1182\/blood-2015-07-657478","volume":"126","author":"V Prasad","year":"2015","unstructured":"Prasad V, Mailankody S. How should we assess the value of innovative drugs in oncology? Lessons from cost-effectiveness analyses. Blood. 2015;126:1860\u20131. https:\/\/doi.org\/10.1182\/blood-2015-07-657478.","journal-title":"Blood"},{"key":"4348_CR106","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.31147","volume":"71","author":"C Mazariego","year":"2024","unstructured":"Mazariego C, Daly R, McGill B, Kelada L, McKay S, Hetherington K, et al. Barriers to access of precision guided therapies for children with high-risk cancer. Pediatr Blood Cancer. 2024;71:e31147. https:\/\/doi.org\/10.1002\/pbc.31147.","journal-title":"Pediatr Blood Cancer"},{"key":"4348_CR107","doi-asserted-by":"publisher","first-page":"71548","DOI":"10.18632\/oncotarget.17742","volume":"8","author":"DA Goldstein","year":"2017","unstructured":"Goldstein DA, Clark J, Tu Y, Zhang J, Fang F, Goldstein R, et al. A global comparison of the cost of patented cancer drugs in relation to global differences in wealth. Oncotarget. 2017;8:71548\u201355. https:\/\/doi.org\/10.18632\/oncotarget.17742.","journal-title":"Oncotarget"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04348-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-026-04348-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04348-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T11:04:38Z","timestamp":1787396678000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-026-04348-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,9]]},"references-count":107,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["4348"],"URL":"https:\/\/doi.org\/10.1007\/s12094-026-04348-y","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,9]]},"assertion":[{"value":"3 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that there are no conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study is a review of previously published literature and did not involve any human participants, animals, or identifiable personal data. Therefore, institutional review board (IRB) approval and informed consent were not required. All sources are appropriately cited.","order":2,"name":"Ethics","label":"Ethical statement and informed consent","group":{"name":"EthicsHeading","label":"Declarations"}}]}}